PhotonPharma Appoints Derek Brown as CEO

Derek Brown, CEO, PhotonPharma Inc. ● Photo Credit: PhotonPharma Inc

FORT COLLINS, Colo., October 28, 2024 (VSNewsNetwork.com) – PhotonPharma Inc., a biopharmaceutical company specializing in the development of autologous cancer immunotherapies, has appointed Derek Brown as its new Chief Executive Officer. Brown takes over from Alan Rudolph, who will step down and remain on the company’s Board of Directors.

Brown has more than 25 years of experience in the biopharmaceutical industry, including roles at Rallybio, Chiasma, and Alexion Pharmaceuticals. At Rallybio, he led the development of the company’s commercial vision and operational plans. At Chiasma, Brown helped prepare for its first commercial launch and contributed to the company’s acquisition by Amryt Pharma.

"Derek's leadership and deep understanding of the biopharmaceutical industry make him the perfect fit for PhotonPharma as we advance the clinical development of our cancer therapy platform, Innocell™”, said Terry Opgenorth PhotonPharma’s Chairman of the Board.

@VSNewsNetwork

@VSNewsNetwork

Brown commented on his new role, stating, "I'm honored to lead PhotonPharma at such a pivotal time in the company's journey. PhotonPharma's differentiated and novel cancer immunotherapy programs show great promise to improve the outcomes for patients with solid tumors."

PhotonPharma’s lead product, Innocell™, received FDA clearance in 2024 for a Phase 1 clinical study in stage III/IV ovarian cancer patients. The trial, conducted in partnership with the City of Hope in Los Angeles, will evaluate the safety and immune response of the therapy.

For more information, visit www.photonpharmaceuticals.com.

Source: PhotonPharma Inc.